Sunifiram shares a pyrrolidinone-derived structural lineage conceptually related to the racetam family but is synthesized via a distinct chemical route and carries substituents not present in piracetam, oxiracetam, or other classical racetam-family compounds. This structural distinction is the basis for research comparing sunifiram's receptor-binding and functional potency profile against established racetam compounds, particularly given reports of substantially different potency ranges between the two groups in similar assay systems.

Patch-clamp electrophysiology in cultured neurons, brain slice preparations, or heterologous expression systems is the standard method for characterising sunifiram's effects on AMPA receptor-mediated currents, with key readouts including peak current amplitude, desensitization rate, and deactivation kinetics in the presence versus absence of the compound. These functional measurements are used alongside receptor-binding assays to determine whether sunifiram acts at an allosteric site distinct from the glutamate orthosteric binding site, consistent with a positive allosteric modulator mechanism.

Reports of sunifiram's in vitro activity describe substantially lower effective concentrations than those required for classical racetam-family compounds in comparable assay systems, prompting researchers to use nanomolar-to-low-micromolar concentration ranges when establishing dose-response curves for sunifiram, in contrast to the micromolar-to-millimolar ranges typically required for piracetam-class compounds. Researchers should empirically establish the relevant concentration range for their specific assay system and cell model rather than assuming direct potency transfer from other reported studies.